InvestorsHub Logo
Followers 4
Posts 119
Boards Moderated 0
Alias Born 06/12/2015

Re: James salmon post# 37048

Tuesday, 10/03/2017 4:54:06 PM

Tuesday, October 03, 2017 4:54:06 PM

Post# of 108192
James, my experience and expectation is that payments on these kinds of deals are strongly back-end weighted with token amounts for interim preclinical and early clinical results. I have not figured those potential $$ into my thinking because I doubt there will be much before 2019. AIM2CERV and Europe are still the two big drivers for this company's future. We simply need cash to get to those outcomes. If we can/ do, then the other stuff (NEO, etc.) simply makes the value of the buy-out that much greater.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News